Rendering DNA Repair Defective by Targeting Wild-type BRCA1 Nuclear Shuttling in Sporadic Breast Cancer as a Therapeutic Agent

2009 ◽  
Author(s):  
Fen Xia
2006 ◽  
Vol 103 (2) ◽  
pp. 209-217 ◽  
Author(s):  
Sandra Costa ◽  
Daniela Pinto ◽  
Deolinda Pereira ◽  
Helena Rodrigues ◽  
Jorge Cameselle-Teijeiro ◽  
...  

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Luisel J Ricks-Santi ◽  
Lara E Sucheston ◽  
Yang Yang ◽  
Jo L Freudenheim ◽  
Claudine J Isaacs ◽  
...  

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Maria J Sambade ◽  
Amanda E D Van Swearingen ◽  
Marni B McClure ◽  
Allison M Deal ◽  
Charlene Santos ◽  
...  

Abstract Background Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of breast cancer susceptibility protein (BRCA)-mutant TNBC. Methods Mice bearing intracranial human-derived TNBC cell lines (SUM149, MDA-MB-231Br, or MDA-MB-436) were treated with niraparib and monitored for survival; intracranial tissues were analyzed for PAR levels and niraparib concentration by mass spectrometry. RNASeq data of primary breast cancers using The Cancer Genome Atlas were analyzed for DNA damage signatures. Combined RAD51 and PARP inhibition in TNBC cell lines was assessed in vitro by colony-forming assays. Results Daily niraparib increased median survival and decreased tumor burden in the BRCA-mutant MDA-MB-436 model, but not in the BRCA-mutant SUM149 or BRCA-wild-type MDA-MB-231Br models despite high concentrations in intracranial tumors. RAD51 inhibitor B02 was shown to sensitize all cell lines to PARP inhibition (PARPi). In the analysis of BRCA-mutant primary human TNBCs, gene expression predictors of PARPi sensitivity and DNA repair signatures demonstrate widespread heterogeneity, which may explain the differential response to PARPi. Interestingly, these signatures are significantly correlated to RAD51 expression including PARPi sensitivity (R2 = 0.602, R2= 0.758). Conclusions Niraparib penetrates intracranial tumor tissues in mouse models of TNBC with impressive single-agent efficacy in BRCA-mutant MDA-MB-436. Clinical evaluation of niraparib to treat TNBC brain metastases, an unmet clinical need desperate for improved therapies, is warranted. Further compromising DNA repair through RAD51 inhibition may further augment TNBC’s response to PARPi.


2015 ◽  
Vol 10 (1) ◽  
pp. 179-193 ◽  
Author(s):  
Chao Liu ◽  
Sriganesh Srihari ◽  
Samir Lal ◽  
Benoît Gautier ◽  
Peter T. Simpson ◽  
...  

Genetika ◽  
2015 ◽  
Vol 47 (2) ◽  
pp. 733-739 ◽  
Author(s):  
Sahar Gohari-Lasaki ◽  
Jalal Gharesouran ◽  
Morteza Ghojazadeh ◽  
Vahid Montazeri ◽  
Hakimeh Saadatian ◽  
...  

DNA-repair systems are essential for repairing damage that occurs when there is recombination between homologous chromosomes. The gene XRCC3 (X-ray cross complementing group 3) encodes a member of the RecA/Rad51-related protein family that participates in homologous recombination to maintain chromosome stability and repair DNA damage. The Thr241Met XRCC3-18067C>T, rs861539) substitution, a C to T transition at codon 241 in exon7, thus plays critical roles in cancer development. The aim of this study was association between XRCC3 Thr241Met polymorphism and risk of sporadic breast cancer in Azari population. We analysed DNA samples from 100 sporadic breast cancer patients and 100 healthy women, for XRCC3 Thr241Met polymorphism using PCR-RFLP. Genotype specific risks were tested using chi-test with 95% confident intervals. Frequency of Thr/Thr at codon 241was 69% in controls and 70% in patients, Thr/Met frequency was 22% in controls and 13 % in patients, the Met/Met genotype was 9% incontrols and 17% in patients. No correlation between the genotype and allele distribution and increased susceptibility for breast Cancer. Our results suggested that in pre-menopausal women, breast cancer riskis not significantly associated with rs861539 in Azari population.


2015 ◽  
Vol 19 (7) ◽  
pp. 387-393 ◽  
Author(s):  
Gongjian Zhu ◽  
Lan Wang ◽  
Hongyun Guo ◽  
Lingeng Lu ◽  
Suisheng Yang ◽  
...  

2018 ◽  
Author(s):  
I Sepahi ◽  
U Faust ◽  
M Sturm ◽  
K Bosse ◽  
M Kehrer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document